Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer.
暂无分享,去创建一个
S. Fosså | A. Horwich | J. Aparicio | H. Haugnes | M. D. De Santis | R. de Wit | U. de Giorgi | T. Gilligan | F. Honecker | J. Beyer | A. Stephenson | S. Gillessen | U. Giorgi | G. Rosti | J. Oldenburg | M. Cullen | J. Germá-Lluch | D. Ondruš | A. Lorch | T. Tandstad | G. Cohn‐Cedermark | M. D. Santis | R. D. Wit | G. Cohn‐cedermark | A. Lorch | Jörg Beyer | S. Fosså | A. Horwich | Silke Gillessen | Jorge Aparicio | Michael H. Cullen | Andrew J. Stephenson
[1] U. Pastorino,et al. Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] M. Ro̸rth,et al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Wit. Optimal Management of Clinical Stage I Nonseminoma: New Data for Patients to Consider , 2014 .
[4] O. Ståhl,et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] J. Carles,et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] C. Albany,et al. Images in clinical medicine. Posterior mediastinal mass. , 2014, The New England journal of medicine.
[7] O. Ståhl,et al. Management of clinical stage I seminomatous testicular cancer: A report from SWENOTECA. , 2014 .
[8] S. Fosså,et al. Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Fosså,et al. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] T. Powles,et al. Active surveillance is the preferred approach to clinical stage I testicular cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. Bosl,et al. Optimal management of clinical stage I testis cancer: one size does not fit all. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] P. Warde,et al. Characterization of relapse in patients with clinical stage I (CSI) nonseminoma (NS-TC) managed with active surveillance (AS): A large multicenter study. , 2013 .
[13] S. Fosså,et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] S. Fosså,et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] X. G. Del Muro,et al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Wahlqvist,et al. Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] G. Rustin,et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] G. Bosl,et al. Carboplatin in clinical stage I seminoma: too much and too little at the same time. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] S. Fosså,et al. Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. , 2010, European urology.
[20] M. Gleave,et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] P. Warde,et al. Prognostic factors for relapse in stage I seminoma managed with surveillance: A validation study. , 2010 .
[22] S. Fosså,et al. Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors , 2009, Journal of the National Cancer Institute.
[23] S. Fosså,et al. Fear of recurrence in long‐term testicular cancer survivors , 2009, Psycho-oncology.
[24] C. Kollmannsberger,et al. Vox populi: Using community-based studies to determine best management of early-stage nonseminoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] R. Bremnes,et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] D. Dearnaley,et al. Prospective study of factors predicting adherence to medical advice in men with testicular cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] S. Fosså,et al. Pulmonary function in long-term survivors of testicular cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] G. Sonn,et al. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. , 2009, The Journal of urology.
[29] D. Dearnaley,et al. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse , 2008, British Journal of Cancer.
[30] C. Saigal,et al. Quality of surveillance for stage I testis cancer in the community. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] D. Brenner,et al. Computed tomography--an increasing source of radiation exposure. , 2007, The New England journal of medicine.
[32] R. Lothe,et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] S. Fosså,et al. Gonadal dysfunction and fertility problems in cancer survivors , 2007, Acta oncologica.
[34] R. de Wit,et al. Controversies in the management of clinical stage I testis cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] S. Fosså,et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] L. Paz-Ares,et al. Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] L. Kavoussi,et al. Modeling the cost of management options for stage I nonseminomatous germ cell tumors: a decision tree analysis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] G. Rustin,et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial , 2005, The Lancet.
[39] M. Moore,et al. Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres. , 2005, The Canadian journal of urology.
[40] S. Fosså,et al. Long-term renal function after treatment for malignant germ-cell tumours. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[41] C. Catton,et al. Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. , 1997, The Journal of urology.
[42] L. Billingham,et al. Management preferences in stage I non-seminomatous germ cell tumours of the testis: an investigation among patients, controls and oncologists. , 1996, British Journal of Cancer.
[43] B. Freedman. Equipoise and the ethics of clinical research. , 1987, The New England journal of medicine.
[44] C. Lawton. Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group , 2012 .
[45] B. Wells,et al. Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] T. Powles,et al. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] U. Studer,et al. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. , 2008, The Journal of urology.
[48] D. Ondruš,et al. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only. , 2007, Neoplasma.
[49] Horton,et al. Annals of Oncology , 1991, Springer US.
[50] C. Waltz. Validation study. , 1988, NLN publications.